<DOC>
	<DOCNO>NCT01268579</DOCNO>
	<brief_summary>Human papillomavirus ( HPV-16 ) important factor development many tonsil and/or base tongue squamous cell cancer . Although HPV-16 thought cause cancer , appear contribute development tonsil and/or base tongue cancer many patient . It likely treatment many patient tonsil and/or base tongue cancer could improve effective therapy control HPV-16 develop . The investigator study want learn ribavirin show evidence activity HPV-16 . Ribavirin pill therapy approve Food Drug Administration ( FDA ) part standard treatment Hepatitis C. Laboratory experiment suggest ribavirin might also useful treatment head neck cancer . However , ribavirin yet test head neck cancer patient . The purpose study find effect ribavirin tonsil base tongue squamous cell cancer patient . The main purpose study see ribavirin change expression certain protein relate HPV infection tumor . The study also find ribavirin change tumor appear PET/CT scan ( positron emission tomography/computed tomography scan ) .</brief_summary>
	<brief_title>Pharmacodynamic Effects Ribavirin Patients With Tonsil and/or Base Tongue Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Prior diagnostic surgical core needle biopsy , confirmation tonsil and/or base tongue squamous cell carcinoma positive expression p16 phosphorylated eIF4E , determine Department Pathology MSKCC . The biopsy may either tonsil base tongue and/or involve neck node . 2 unstained slide and/or tissue block must available initial diagnostic biopsy Positive expression p16 phosphorylated eIF4E define &gt; =30 % tumor cell cytological and/or nuclear stain Age ≥ 18 ≤ 65 year age Karnofsky Performance Status ≥ 80 Adequate organ function , follow : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1.5 X 109/L , platelet ≥ 160 X 109/L , hemoglobin ≥ 12 g/dL Hepatic : total bilirubin within 1.5 X upper limit normal ( ULN ) ; alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 X ULN ( Patients Gilbert 's syndrome cause hyperbilirubinemia may eligible total bilirubin ≤ 2.5 X UNL ) Renal : Serum creatinine ≤ 1.3 mg/dL . Patients serum creatinine &gt; 1.3 mg/dL may eligible creatinine clearance ( CrCl ) ≥ 55 mL/min base standard Cockroft Gault formula . Patients childbearing potential must negative serum pregnancy test within 14 day treatment . Patients must agree use reliable method birth control 6 month follow last dose study drug . Ability swallow oral medication . Nonsurgical patient : If primary radiation +/ chemotherapy ( concurrent sequential ) plan , patient must agree undergo research biopsy completion ribavirin treatment . Prior chemotherapy radiation tonsillar base tongue squamous cell cancer More 10 packyears tobacco use History hemolytic anemia thalassemia Active infection serious underlie medical condition would impair patient 's ability receive protocol treatment . Current therapeutic anticoagulation Coumadin ( warfarin ) Current prior treatment ribavirin Known active Hepatitis B C Any prior document history transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) New York Heart Association ( NYHA ) Grade II great congestive heart failure Clinically significant peripheral vascular disease History unstable angina myocardial infarction ( MI ) within last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ribavirin</keyword>
	<keyword>VIRAZOLE</keyword>
	<keyword>tonsil</keyword>
	<keyword>base tongue</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>10-218</keyword>
</DOC>